Highlighting Success in Antibody Shuttle-Mediated Transportation for Amyloid-Targeted Therapeutics

Time: 2:45 pm
day: Conference Day Two


  • Identifying the optimal bispecific antibody format for maximizing CNS exposure
  • AT-07, the conjugation of AT-04 to a VNAR-derived brain shuttle, enhanced brain penetration in a mouse model and has the potential to increase effectiveness in clearing neuropathic fibrillar deposits
  • AT-07 demonstrated a 10-fold increase in brain penetration versus AT-04 in a PK study in wild-type mice